Morningside Ventures leads a Series B round for DNAtrix
DNAtrix has closed $20 million in Series B financing. Morningside Ventures led the round with participation from previous backers that include Mercury Fund and Targeted Technology Fund. In addition to the funding, the company has added Reenie McCarthy of Morningside to its board of directors. Based in Houston and San Diego, DNAtrix is a a clinical-stage oncolytic immunotherapy firm.
14 October 2014•2 mins read
